These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28187492)

  • 61. Personalized medicine: a patient-centered paradigm.
    Chouchane L; Mamtani R; Dallol A; Sheikh JI
    J Transl Med; 2011 Dec; 9():206. PubMed ID: 22133076
    [No Abstract]   [Full Text] [Related]  

  • 62. Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?
    Shimazawa R; Ikeda M
    Br J Clin Pharmacol; 2013 May; 75(5):1365-7. PubMed ID: 22978372
    [No Abstract]   [Full Text] [Related]  

  • 63. Personalized medicine: factors influencing reimbursement.
    Meckley LM; Neumann PJ
    Health Policy; 2010 Feb; 94(2):91-100. PubMed ID: 19815307
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Response to the comments from Drs Shimazawa and Ikeda.
    Shah RR; Shah DR
    Br J Clin Pharmacol; 2013 May; 75(5):1368-9. PubMed ID: 22978350
    [No Abstract]   [Full Text] [Related]  

  • 65. Genomic Database Grows.
    Eissenberg JC
    Mo Med; 2017; 114(3):151. PubMed ID: 30228568
    [No Abstract]   [Full Text] [Related]  

  • 66. Preserving data privacy when using multi-site data to estimate individualized treatment rules.
    Danieli C; Moodie EEM
    Stat Med; 2022 Apr; 41(9):1627-1643. PubMed ID: 35088914
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predicting the cost and pace of pharmacogenomic advances: an evidence-based study.
    Arnaout R; Buck TP; Roulette P; Sukhatme VP
    Clin Chem; 2013 Apr; 59(4):649-57. PubMed ID: 23230323
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacogenomic-guided drug development: regulatory perspective.
    Lesko LJ; Woodcock J
    Pharmacogenomics J; 2002; 2(1):20-4. PubMed ID: 11990376
    [No Abstract]   [Full Text] [Related]  

  • 69. Pharmacogenomic personalised medicine for antiplatelet agents is on the horizon.
    Floyd CN
    BMJ; 2012 Jun; 344():e4198. PubMed ID: 22718899
    [No Abstract]   [Full Text] [Related]  

  • 70. Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy.
    Darwich AS; Polasek TM; Aronson JK; Ogungbenro K; Wright DFB; Achour B; Reny JL; Daali Y; Eiermann B; Cook J; Lesko L; McLachlan AJ; Rostami-Hodjegan A
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():225-245. PubMed ID: 33035445
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol).
    Bielinski SJ; St Sauver JL; Olson JE; Larson NB; Black JL; Scherer SE; Bernard ME; Boerwinkle E; Borah BJ; Caraballo PJ; Curry TB; Doddapaneni H; Formea CM; Freimuth RR; Gibbs RA; Giri J; Hathcock MA; Hu J; Jacobson DJ; Jones LA; Kalla S; Koep TH; Korchina V; Kovar CL; Lee S; Liu H; Matey ET; McGree ME; McAllister TM; Moyer AM; Muzny DM; Nicholson WT; Oyen LJ; Qin X; Raj R; Roger VL; Rohrer Vitek CR; Ross JL; Sharp RR; Takahashi PY; Venner E; Walker K; Wang L; Wang Q; Wright JA; Wu TJ; Wang L; Weinshilboum RM
    Int J Epidemiol; 2020 Feb; 49(1):23-24k. PubMed ID: 31378813
    [No Abstract]   [Full Text] [Related]  

  • 72. Eyes on the prize: bringing individualized therapy from the bedside to clinical practice.
    Peters J
    Pharmacogenomics; 2007 Oct; 8(10):1295-8. PubMed ID: 17979503
    [No Abstract]   [Full Text] [Related]  

  • 73. Equity in Precision Medicine: Is It Within Our Reach?
    Armstrong K
    J Natl Compr Canc Netw; 2017 Mar; 15(3):421-423. PubMed ID: 28275040
    [No Abstract]   [Full Text] [Related]  

  • 74. Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate.
    Gunter L; Zhu J; Murphy S
    J Biopharm Stat; 2011 Nov; 21(6):1063-78. PubMed ID: 22023676
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
    Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
    Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis.
    Jiang S; Mathias PC; Hendrix N; Shirts BH; Tarczy-Hornoch P; Veenstra D; Malone D; Devine B
    Pharmacogenomics J; 2022 May; 22(3):188-197. PubMed ID: 35365779
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.
    Guzauskas GF; Basu A; Carlson JJ; Veenstra DL
    Value Health; 2019 Sep; 22(9):988-994. PubMed ID: 31511188
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.
    Dhanda DS; Guzauskas GF; Carlson JJ; Basu A; Veenstra DL
    Clin Pharmacol Ther; 2017 Nov; 102(5):805-814. PubMed ID: 28187492
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Personalized medicine: potential, barriers and contemporary issues.
    Sorich MJ; McKinnon RA
    Curr Drug Metab; 2012 Sep; 13(7):1000-6. PubMed ID: 22591350
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis.
    Tang Q; Zou H; Guo C; Liu Z
    Int J Cardiol; 2014 Aug; 175(3):587-91. PubMed ID: 25005340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.